Viemed Healthcare, Inc. VMD R2KR3KPHARMA
Company Overview
Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. It also sells and rents HME devices, such as non-invasive and invasive ventilators, positive airway pressure (PAP) machines, durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment. In addition, the company provides neuromuscular care and oxygen therapy services; and sleep apnea management which provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, it offers in-home sleep apnea testing services; and breast pumps and related lactation equipment and supplies, including fulfillment and support services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.
Why Investors Should Care
Revenue has grown at a 27.0% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.08.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $270.28M (+20.5% YoY); net profit $14.93M.
- Trailing 12 Months Year-on-year growth — revenue +23.9%, earnings -12.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 27.0%, profit CAGR 7.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 26.98% |
| 1 Year: | 23.90% |
Compounded Profit Growth
| 5 Years: | 7.82% |
| 1 Year: | -12.40% |
Stock Price Performance
| 1 Year: | +33.70% |
| 6 Months: | +1.45% |
| 3 Months: | -19.14% |
| 1 Month: | +11.11% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)61.74 · Neutral
P/E of 27.22 is above the sector median of 25.45 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 27.0% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VMD Viemed Healthcare, Inc. R2KR3KPHARMA | 9.80 | 27.22 | $373.26M | 0.00% | 13.10% | 10.45% | 26.98% | 7.82% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.96M | 15.21M | 16.93M | 18.36M | 18.11M | 20.32M | 20.37M | 21.45M | 23.81M | 42.85M | 33.45M | 31.20M | 28.42M | 27.40M | 29.29M | 32.26M | 33.31M | 35.76M | 39.56M | 43.31M | 49.40M | 50.59M | 54.97M | 58.00M | - | 59.13M | 63.06M | 71.91M | 76.18M | 75.41M | 78.10M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25.85M | 26.32M | 30.57M | 32.08M | 32.59M | - |
| Gross Profit | 10.40M | 11.02M | 12.83M | 13.52M | 13.07M | 14.64M | 14.05M | 14.24M | 15.55M | 25.93M | 19.45M | 19.18M | 17.74M | 17.62M | 18.38M | 19.74M | 20.39M | 21.65M | 24.00M | 26.11M | 30.56M | 29.80M | 32.89M | 34.37M | - | 33.28M | 36.73M | 41.34M | 44.10M | 42.83M | 45.05M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 31.81M | 32.27M | 35.23M | 35.44M | 38.17M | - |
| Operating Income | 2.34M | 2.29M | 2.51M | 2.92M | 2.32M | 1.66M | 2.19M | 2.69M | 4.62M | 12.86M | 4.04M | 5.27M | 1.33M | 2.66M | 2.92M | 2.25M | 1.00M | 1.47M | 1.93M | 2.90M | 4.21M | 2.20M | 3.62M | 5.63M | - | 1.47M | 4.46M | 6.12M | 8.66M | 4.65M | 4.46M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.45M | 11.35M | 13.18M | 15.94M | 11.92M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 147.00K | 179.00K | - | 507.00K | 364.00K | 305.00K | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.66M | 4.96M | 5.13M | 8.01M | 3.99M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 952.00K | 1.71M | 1.53M | 2.19M | 1.28M | - |
| Net Income | 2.22M | 2.10M | 2.22M | 2.97M | 1.96M | 1.33M | 2.85M | 2.39M | 4.24M | 19.41M | 2.80M | 5.07M | 1.68M | 1.57M | 1.79M | 1.76M | 967.00K | 1.05M | 1.52M | 2.33M | 2.92M | 1.60M | 1.47M | 3.88M | - | 2.62M | 3.16M | 3.51M | 5.64M | 2.58M | 2.76M |
| Diluted EPS | 0.06 | 0.05 | 0.06 | 0.07 | 0.05 | 0.03 | 0.07 | 0.06 | 0.11 | 0.48 | 0.07 | 0.12 | 0.04 | 0.04 | 0.04 | 0.04 | 0.02 | 0.03 | 0.04 | 0.06 | 0.07 | 0.04 | 0.04 | 0.10 | - | 0.06 | 0.08 | 0.09 | 0.14 | 0.06 | 0.07 |
| R&D Expense | 0 | 0 | 0 | 0 | 234.00K | 203.00K | 208.00K | - | 174.00K | 271.00K | 243.00K | - | 339.00K | 583.00K | 576.00K | 632.00K | 672.00K | 670.00K | 780.00K | 758.00K | 593.00K | 750.00K | 758.00K | 757.00K | - | 797.00K | 847.00K | 775.00K | - | 579.00K | 504.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 64.46M | 80.26M | 131.31M | - | 138.83M | 183.01M | 224.26M | 270.28M |
| Cost of Revenue | - | - | - | - | 54.15M | 70.22M | 91.05M | 114.82M |
| Gross Profit | 47.77M | 56.01M | 80.11M | - | 84.68M | 112.78M | 133.20M | 155.46M |
| Operating Expenses | - | - | - | - | 76.08M | 97.81M | 117.21M | 134.75M |
| Operating Income | 10.06M | 8.86M | 26.78M | - | 8.60M | 14.97M | 15.99M | 20.71M |
| EBITDA | - | - | - | - | 24.82M | 36.68M | 42.31M | 51.56M |
| Interest Expense | - | - | - | - | 197.00K | 424.00K | 776.00K | 1.18M |
| Pretax Income | - | - | - | - | 8.99M | 14.39M | 16.17M | 21.77M |
| Tax Provision | - | - | - | - | 2.77M | 4.15M | 4.76M | 6.39M |
| Net Income | 9.51M | 8.53M | 31.53M | - | 6.22M | 10.24M | 11.27M | 14.93M |
| Diluted EPS | 0.24 | 0.21 | 0.78 | - | 0.16 | 0.25 | 0.28 | 0.37 |
| R&D Expense | 0 | 848.00K | 1.08M | 2.11M | 2.70M | 2.78M | 3.07M | 3.02M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 40.66M | 44.26M | 49.24M | 53.65M | 58.72M | 71.01M | 79.98M | 82.60M | 112.56M | - | 117.04M | 154.90M | 177.07M | 199.15M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 39.74M | 38.37M | 52.88M | 48.49M |
| Cash & Equivalents | - | 4.63M | 8.55M | 10.17M | 10.41M | 7.41M | 7.69M | 12.63M | 13.36M | 30.98M | - | 16.91M | 12.84M | 17.54M | 13.50M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | 3.57M | 4.63M | 4.32M | 5.05M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | 15.38M | 18.45M | 24.91M | 25.59M |
| Total Liabilities | - | 15.92M | 16.76M | 18.85M | 21.08M | 24.83M | 34.88M | 39.66M | 38.90M | 30.87M | - | 19.95M | 41.00M | 43.77M | 55.63M |
| Current Liabilities | - | 14.61M | 15.46M | 17.19M | 19.57M | 21.68M | 27.39M | 26.55M | 25.91M | 23.02M | - | 18.86M | 32.12M | 37.33M | 41.06M |
| Long Term Debt | - | 0 | 0 | 0 | 0 | 0 | 4.70M | 8.08M | 7.63M | 5.80M | 4.31M | - | 6.00M | 3.59M | 11.29M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 694.00K | 10.32M | 6.87M | 15.95M |
| Total Equity | 21.95M | 24.74M | 27.50M | 30.39M | 32.57M | 33.89M | 36.14M | 40.32M | 43.70M | 81.69M | - | 97.09M | 113.89M | 131.39M | 141.54M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 38.05M | 38.51M | 39.13M | 38.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 22.37M | 19.09M | 35.11M | - | 27.75M | 45.21M | 39.09M | 51.92M |
| Investing Cash Flow | -5.30M | -12.81M | -8.41M | - | -23.98M | -52.11M | -30.70M | -50.17M |
| Financing Cash Flow | -11.75M | -3.33M | -9.07M | - | -15.27M | 2.83M | -3.69M | -5.79M |
| Capital Expenditure | -6.11M | -13.38M | -13.04M | - | -22.90M | -26.09M | -37.77M | -39.98M |
| Free Cash Flow | 16.25M | 5.70M | 22.07M | - | 4.85M | 19.12M | 1.32M | 11.93M |
| Net Change in Cash | - | - | - | - | -11.49M | -4.08M | 4.70M | -4.04M |
| Share Buybacks | 1.59M | 1.52M | 0 | 0 | 9.57M | 0 | 0 | 13.22M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 74.1% | 69.8% | 61.0% | - | 61.0% | 61.6% | 59.4% | 57.5% |
| Operating Margin % | 15.6% | 11.0% | 20.4% | - | 6.2% | 8.2% | 7.1% | 7.7% |
| Net Margin % | 14.7% | 10.6% | 24.0% | - | 4.5% | 5.6% | 5.0% | 5.5% |
| ROE % | 29.2% | 19.5% | 38.6% | - | 6.4% | 9.0% | 8.6% | 10.6% |
| ROCE % | 29.5% | 15.6% | 29.9% | - | 8.8% | 12.2% | 11.4% | 13.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 12.57% | 4.79M | $45.58M |
| 2 | Forager Capital Management, LLC | 5.62% | 2.14M | $20.38M |
| 3 | Vanguard Capital Management LLC | 3.47% | 1.32M | $12.58M |
| 4 | Goldman Sachs Group Inc | 3.21% | 1.22M | $11.64M |
| 5 | Ameriprise Financial, Inc. | 2.64% | 1.01M | $9.58M |
| 6 | Geode Capital Management, LLC | 2.56% | 973.74K | $9.27M |
| 7 | Arrowstreet Capital, Limited Partnership | 2.06% | 786.27K | $7.49M |
| 8 | State Street Corporation | 2.00% | 762.10K | $7.26M |
| 9 | Nantahala Capital Management, LLC | 1.66% | 632.45K | $6.02M |
| 10 | PanAgora Asset Management, Inc. | 1.41% | 538.62K | $5.13M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VMD
A live webcast will carry Viemed’s Nov. 5 earnings call. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPMms5SVVsYS1OMHRXcGVCU1NXYkF0b3M0VS1qWGxkTEMzUXdLbjg5T1lNakZ6dGpaX2FUVHA3QTJqcUhUSUxKcWtfaEVXN2g1aEZoZlI4V1I4emdvNmFTQmN5SldISkgtWkFrUzFYcG9sRF9KNF82Z05ERlVDRGRRWHZqZmJaV3E5eUE2MX…
Viemed Healthcare, Inc. (VMD) Lags Q2 Earnings Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOTDYtbGt0azNvTDBhVTVNZmZ6dGVnMlI5ZGtBNUhhMUlPY0hlOEtYUG8xM3pWWlR2WnYyV3BzcFlSUEdtYkVYVVc3LWlGZ3JEdU1hX01yOVBtSVNwOTJCU0I4UVFCZmpYSF9sUHFvbjZXNFowMTRlQkJIMTdBWlVPbHhDSVdGUEVNM2h4VE…
Viemed Healthcare: Improving Capital Efficiency Creates A Strong Buy Opportunity (NASDAQ:VMD) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPMXkxR2F5OEpKSE1yeHVfNjhzT29JX2l1OG9FOVNBRGt4eXZ2QjByZjVta2R4QmJWM2dmdGlVb1g2ZUJ5X3kwTmtyeWpCcTNQa3RjcmdSencxNERmQXlkenkxMV9WWW5pX29CVFMxVTlUcjdlTm1wQXhjaUNjbmFrVWtGc280aXAzT3NQZE…
Viemed Healthcare Q3 2026 Earnings Date and Estimates - MarketBeat
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQTE1NWF9FS2txTHJUcTBrbHNpcmNHSVI3c1BlOWxrNTFTV3Bwek1kU3RvY2gzZExudUN0T3QzcHRZT2hpdkd3cDdCdE9KRk5qUHd1VlU4Y3VhWmJtV011RTNOc1IyUkhUZ1pwZm43VDJPVXVmdXphSkFmVzI4cVRjTUhQZzlPTzlFTFFxZQ…
Viemed Healthcare (VMD) Stock Fair Value Rises After Mixed Analyst Views On Profitability - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPMFhORHFtY3lZV2pOSUtKZm95UjZDUFJMR25ETkZGYnQ0c3ZGMVhQTVdqbFgxQk1LbFR1UWRPNXpZeTZSLTNHSjFXRHY1czhvSzhjblNlZ1lvTzZoZmF2SENvUG9ZR3ZDamMzY25qTC1TR1FweHBSM1Z3UEJrbHVpdWVOa3l3R0I5TldmaG…
Do Options Traders Know Something About Viemed Stock We Don't? - TradingView
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQS3A3eElPSWtZMkxnN2ZVemkyR1NBVTBSdkRMNG9FaGtZTURRZFlMUXdERDdBdk1kdTBPanhEMndZUUZrakljdzQ5OC0tZE9rUVBPdU5zcXd0bXV5SjNfNlpScXlodElzaEtzRXktZW83Q3JqcUJLVWRPdHB3QTF0RDYxSEpFcy1LRWJ0VW…
VMD — Frequently Asked Questions
What is the current share price of Viemed Healthcare, Inc. (VMD)?
As of 2026-10-23 16:27 PDT, Viemed Healthcare, Inc. (VMD) trades at $9.80 on NasdaqCM. Its 52-week range is $6.26 to $12.33.
What is the market capitalisation of VMD?
Viemed Healthcare, Inc. (VMD) has a market capitalisation of $373.26M on NasdaqCM.
What is the P/E ratio of VMD?
VMD trades at a trailing price-to-earnings (P/E) ratio of 27.22. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 2.36.
What is the return on equity (ROE) of VMD?
VMD has a return on equity (ROE) of 10.45%. Its return on capital employed (ROCE) is 13.10%.
Is VMD a good stock to buy?
This page provides a data-driven analysis of Viemed Healthcare, Inc. (VMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.